Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 198

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 198
---
 23, 2024, in accordance with ASC 810, Lipovation’s financial statement
are presented as the “Predecessor” for periods prior to the closing of the acquisition. Revium Rx, which includes consolidation
of Lipovation Ltd subsequent to the acquisition, is the “Successor” for periods after the closing of the Business Combination.
As a result of the application of the acquisition method of accounting in the Successor period, the financial statements for the Successor
period are presented on a full step-up basis as a result of the acquisition and are therefore not comparable to the financial statements
of the Predecessor period that are not presented on the same full step-up basis.

<div align='center'>F-9</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (Cont.)

Successor

The consolidated
Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S.
GAAP”).

| a. | Use of estimates in preparation of Financial Statements: |

The preparation
of consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions
that affect the amounts reported in the consolidated Financial Statements and accompanying notes. The Company evaluates on an ongoing
basis its assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based
upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated Financial Statements, and the reported
amounts of expenses during the reporting periods. Actual results could differ from those estimates.

As applicable
to the consolidated Financial Statements, the most significant estimates and assumptions relate to the going concern assumptions, valuating
fair value of shares received as part of Lipovation’s acquisition, impairment of goodwill and impairment of indefinite intangibles are
considered substantial.

| b. | Business combination |

The Company
allocates the fair value of consideration transferred in a business combination to the assets acquired, liabilities assumed, and non-controlling
interests in the acquired business based on their fair values at the acquisition date. All assets and liabilities are recognized in fair
value. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition
date with respect to intangible assets. Direct transaction costs associated